First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.

Alan Celik Tobias BergLise Birk NielsenMaj-Britt JensenBent EjlertsenAnn KnoopMichael Andersson

Published in: Breast cancer : basic and clinical research (2022)

This retrospective real-world, nationwide study demonstrated comparable median PFS to the historical data of using reference trastuzumab and pertuzumab as first-line dual blockade.

Keyphrases

metastatic breast cancer
electronic health record
epidermal growth factor receptor
big data
machine learning
data analysis
artificial intelligence